CLARICOR trial
Jump to navigation
Jump to search
Introduction
Multicenter, placebo-controlled study in Denmark 13,702 participants, age 18-85 with angina pectoris or myocardial infarction
Protocol:
- a single 14 day course of clarithromycin vs placebo
- 3 year follow-up
Primary outcome:
- composite all cause mortality, myocardial infarction unstable angina
Secondary outcome:
- composite cardiovascular mortality, myocardial infarction, unstable angina
Results:
- no difference in primary outcome (Hazzard ratio 1.15)
- increased cardiovascular mortality in patients with heart disease 1 year after 14 day course of clarithromycin (Hazzard ratio 1.27-1.45)
More general terms
Additional terms
References
- ↑ Prescriber's Letter 13(1): 2006 Clarithromycin mortality alert for patients with heart disease Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220110&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Jespersen CM et al Randomised placebo controlled multicentre trial to assess short-term clarithromycin for patients with stable coronary heart disease. CLARICOR trial. BMJ 2006, 332:22 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16339220